Explore GEN family of websites, social media experiences, blogs and more.

Unleashing ideas.
Strengthening startups.

Back to search results
    Date submitted
  • 03-Jun-2018

BHAAM Innovations

Abstract

BHAAM Innovations is developing Surestop, a proprietary osmotic delivery device of disulfiram for alcohol abuse. The depot of disulfiram is injected subcutaneously into the lower abdomen where it slowly releases Disulfiram over a 3 months time. Disulfiram causes patients to exhibit hangover symptoms almost immediately upon ingestion of alcohol, making it extremely effective at dissuading further consumption if taken properly. Currently, Disulfiram is taken as an oral pill daily, a single day lapse in taking the medication is enough to allow a patient who is struggling with alcohol addiction the opportunity to relapse. Surestop provides a three month long administration to increase adherence to treatment. It also incorporates an ethanol probe that monitors BAC and reports it via bluetooth to a cell phone.

Additional Questions

Who is your customer?

The initial target market will be patients with court ordered disulfiram use. This patient population specifically requires compliance to the disulfiram dosage. Use of Surestop would save courts the cost of paying for patients to be tested for compliance daily at pharmacies or clinics. Initial marketing efforts will include advertising to court rehabilitation programs. After, adolescents being treating for AUD will be targeted. Parents often monitor compliance of daily disulfiram pills for adolescents suffering from AUD. This is a cumbersome process for the parents and often does not always ensure compliance. The final market targeted will be adults suffering from AUD. Once the depot has been successfully integrated in the initial two target populations, it can be marketed for and brought to be the new standard for adults with AUD.

What problem does this idea/product solve or what market need does it serve?

Disulfiram is an acetaldehyde dehydrogenase (ALDH) enzyme inhibitor used to treat chronic alcohol abuse. Disulfiram causes patients to exhibit hangover symptoms almost immediately upon ingestion of alcohol, making it extremely effective at dissuading further consumption. Disulfiram is currently prescribed as an oral dose to be taken daily (250-500 mg). Disulfiram prescriptions have been steadily declining due to high rates of non-adherence. Disulfiram is taken as an oral pill daily, a single day lapse in taking the medication is enough to allow a patient who is struggling with alcohol addiction the opportunity to relapse. This inherent paradigm of relying on an addict to make the difficult decision daily to take their medication has made adherence the number one barrier to disulfiram success.

What attributes will make this idea/product successful? Why do you believe that those features will create success?

Surestop provides the same dosage, efficacy, and safety of daily oral disulfiram pills while eliminating the adherence barrier that often causes the treatment to fail (ensures adherence to treatment for up to 3 months). It also increases the ease of use of the treatment, decreases the daily burden for the patient and caretaker, and reduces the cost of disulfiram treatment. Surestop will deliver disulfiram directly into hepatic portal circulation, decreasing the total daily dose requirements compared to oral intake, and thus simultaneously decrease any toxic drug byproducts. Lastly, ethanol monitoring will allow for third parties such as parents and caregivers to track alcohol intake in real time, as well as rapidly respond to any potential alcohol induced drug toxicities.

Explain how you (your team) will execute to make this idea/product successful? What gives you (your team) an advantage over others already in the market or new to this market?

We currently hold IP on the implantable Disulfiram pump and the ethanol reporting probe. Our team consists of PhD bioengineering students with expertise in Drug Delivery and Medical school students with a focus in drug addiction. We also have mentors in industry to help guide our decision making. We have been approached by possible acquirers but are wishing to develop the product further prior to acquisition.